PL3810279T3 - Kombinacja obejmująca użycie związku oligopeptydowego i przeciwciała anty-pd-1 lub pd-l1 do stosowania w leczeniu chorób nowotworowych - Google Patents
Kombinacja obejmująca użycie związku oligopeptydowego i przeciwciała anty-pd-1 lub pd-l1 do stosowania w leczeniu chorób nowotworowychInfo
- Publication number
- PL3810279T3 PL3810279T3 PL19734322.1T PL19734322T PL3810279T3 PL 3810279 T3 PL3810279 T3 PL 3810279T3 PL 19734322 T PL19734322 T PL 19734322T PL 3810279 T3 PL3810279 T3 PL 3810279T3
- Authority
- PL
- Poland
- Prior art keywords
- antibody
- combination
- neoplastic conditions
- treating neoplastic
- oligopeptidic compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000001613 neoplastic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1810058.6A GB201810058D0 (en) | 2018-06-19 | 2018-06-19 | Combination therapy using a peptide |
PCT/EP2019/066295 WO2019243471A1 (en) | 2018-06-19 | 2019-06-19 | Combination therapy using a peptide |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3810279T3 true PL3810279T3 (pl) | 2024-02-26 |
Family
ID=63042825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL19734322.1T PL3810279T3 (pl) | 2018-06-19 | 2019-06-19 | Kombinacja obejmująca użycie związku oligopeptydowego i przeciwciała anty-pd-1 lub pd-l1 do stosowania w leczeniu chorób nowotworowych |
Country Status (13)
Country | Link |
---|---|
US (1) | US20210154268A1 (pl) |
EP (1) | EP3810279B1 (pl) |
JP (1) | JP2021527677A (pl) |
KR (1) | KR20210022669A (pl) |
AU (1) | AU2019291079A1 (pl) |
CA (1) | CA3103905A1 (pl) |
DK (1) | DK3810279T3 (pl) |
ES (1) | ES2960783T3 (pl) |
GB (1) | GB201810058D0 (pl) |
IL (1) | IL279461A (pl) |
PL (1) | PL3810279T3 (pl) |
SG (1) | SG11202012768XA (pl) |
WO (1) | WO2019243471A1 (pl) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112019023992A2 (pt) | 2017-05-19 | 2020-06-16 | Wuxi Biologics (Shanghai) Co., Ltd. | Anticorpo ou fragmento de ligação ao antígeno do mesmo, seu método de produção, seus usos, bem como molécula de ácido nucleico, vetor de clonagem ou expressão, célula hospedeira, hibridoma, composição farmacêutica e imunoconjugado |
GB202000167D0 (en) | 2020-01-07 | 2020-02-19 | Cytovation As | Composition for treatment of neoplastic lesions |
KR20240076600A (ko) | 2022-11-22 | 2024-05-30 | 두산에너빌리티 주식회사 | 루트부 체결력이 향상된 블레이드 및 이를 포함하는 풍력발전기 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201001602D0 (en) * | 2010-02-01 | 2010-03-17 | Cytovation As | Oligopeptidic compounds and uses therof |
KR20160079114A (ko) * | 2013-11-11 | 2016-07-05 | 아르모 바이오사이언시스 인코포레이티드 | 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법 |
CA2990107A1 (en) * | 2015-06-24 | 2016-12-29 | Immodulon Therapeutics Limited | A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy |
US20190175748A1 (en) * | 2016-03-16 | 2019-06-13 | Amal Therapeutics Sa | Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine |
-
2018
- 2018-06-19 GB GBGB1810058.6A patent/GB201810058D0/en not_active Ceased
-
2019
- 2019-06-19 AU AU2019291079A patent/AU2019291079A1/en active Pending
- 2019-06-19 DK DK19734322.1T patent/DK3810279T3/da active
- 2019-06-19 PL PL19734322.1T patent/PL3810279T3/pl unknown
- 2019-06-19 SG SG11202012768XA patent/SG11202012768XA/en unknown
- 2019-06-19 KR KR1020217001536A patent/KR20210022669A/ko unknown
- 2019-06-19 WO PCT/EP2019/066295 patent/WO2019243471A1/en unknown
- 2019-06-19 ES ES19734322T patent/ES2960783T3/es active Active
- 2019-06-19 EP EP19734322.1A patent/EP3810279B1/en active Active
- 2019-06-19 US US17/252,424 patent/US20210154268A1/en active Pending
- 2019-06-19 CA CA3103905A patent/CA3103905A1/en active Pending
- 2019-06-19 JP JP2020570822A patent/JP2021527677A/ja active Pending
-
2020
- 2020-12-15 IL IL279461A patent/IL279461A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3810279B1 (en) | 2023-09-13 |
US20210154268A1 (en) | 2021-05-27 |
CN112566699A (zh) | 2021-03-26 |
GB201810058D0 (en) | 2018-08-08 |
IL279461A (en) | 2021-01-31 |
KR20210022669A (ko) | 2021-03-03 |
EP3810279A1 (en) | 2021-04-28 |
AU2019291079A1 (en) | 2021-01-28 |
WO2019243471A1 (en) | 2019-12-26 |
CA3103905A1 (en) | 2019-12-26 |
ES2960783T3 (es) | 2024-03-06 |
JP2021527677A (ja) | 2021-10-14 |
DK3810279T3 (da) | 2023-10-23 |
SG11202012768XA (en) | 2021-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3889179A4 (en) | BISPECIFIC ANTIBODIES AND USE THEREOF | |
IL266424B1 (en) | A bispecific antibody against bcma and cd3 and an immunological drug for combined treatment in multiple myeloma | |
IL276872A (en) | Dosage for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies | |
IL279455A (en) | ANTI-PD-1 antibodies and their uses | |
GB201805963D0 (en) | PD-L1 Binding Affirmers and Uses Related Thereto | |
EP3716165A4 (en) | COMPANY VALUATION SYSTEM BASED ON ESG CRITERIA AND ITS OPERATING PROCESS | |
IL290255A (en) | Anti-ctla4/anti-pd-1 bispecific antibody and its uses | |
IL279251A (en) | Methods for treating cancer with bispecific antibodies against CD3XMUC16 and antibodies against PD-1 | |
IL275577A (en) | Antibodies and their variants against PD-L1 | |
PL3810279T3 (pl) | Kombinacja obejmująca użycie związku oligopeptydowego i przeciwciała anty-pd-1 lub pd-l1 do stosowania w leczeniu chorób nowotworowych | |
ZA202004907B (en) | Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
ZA202006255B (en) | Anti-pd-l1 antibody and use thereof | |
EP3901172A4 (en) | HUMANIZED ANTI-PD-1 ANTIBODIES AND THEIR USE | |
EP3819313A4 (en) | BISPECIFIC ANTIBODIES AND ITS USE | |
IL276675A (en) | Anti-PD-1 antibodies and uses thereof | |
IL285569A (en) | Anti-pd-l1 antibody and use thereof | |
SG11202103221QA (en) | Anti pd-l1 antibody and use thereof | |
IL282478A (en) | Materials and methods for cancer treatment | |
SG11202111188VA (en) | Anti-cd40 antibody and use thereof | |
IL288692A (en) | A bispecific antibody against a-syn/igf1r and its use | |
EP3774920A4 (en) | ANTI-PD-L1 ANTIBODIES AND USE OF THESE LATEST | |
IL283180A (en) | Anti-PD-1 antibodies and their uses | |
SG11202111441QA (en) | Bispecific antibodies against pd-1 and lag-3 | |
EP3826980C0 (en) | COMPOSITION AND METHOD FOR PROCESSING UREA | |
EP3914623A4 (en) | ANTI-PD-L1 DIABODIES AND THEIR USE |